BK7508 Pharmaceutical Companies
Not Yet Opened 10-21 16:00:00 AEDT
714.00
-2.82
-0.39%
High725.39Low711.47Vol49.10M
Open723.58D1 Closing716.81Amplitude1.94%
Mkt Cap0.00Tradable Cap0.00Total Shares0.00
T/O128.37MT/O Rate--Tradable Shares0.00
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

CSL Limited Appoints Deborah Waterhouse as CEO and Managing Director
Reuters  ·  10-21 13:42
CSL Limited Appoints Deborah Waterhouse as CEO and Managing Director
Australia's CSL Appoints Deborah Waterhouse as CEO
Reuters  ·  10-21 13:42
Australia's CSL Appoints Deborah Waterhouse as CEO
Gordon Naylor to Continue as Interim CEO Until 1 February 2027
THOMSON REUTERS  ·  10-21 13:37
Gordon Naylor to Continue as Interim CEO Until 1 February 2027
Deborah Waterhouse Base Salary Set at £1.50 Mln Per Annum
THOMSON REUTERS  ·  10-21 13:37
Deborah Waterhouse Base Salary Set at £1.50 Mln Per Annum
Appoints Deborah Waterhouse as CEO and Managing Director Effective 1 February 2027
THOMSON REUTERS  ·  10-21 13:37
Appoints Deborah Waterhouse as CEO and Managing Director Effective 1 February 2027
CSL Limited-Appointment of New CEO
THOMSON REUTERS  ·  10-21 13:37
CSL Limited-Appointment of New CEO
Australia's Invion Rises After Securing Clinical Trial Funding Arrangements
Reuters  ·  10-21 10:30
Australia's Invion Rises After Securing Clinical Trial Funding Arrangements
Invion Ltd Says Funding Agreements Cover up to 85% of Clinical Trials Costs
Reuters  ·  10-21 09:21
Invion Ltd Says Funding Agreements Cover up to 85% of Clinical Trials Costs
Actinogen Medical - Narrow Guidance for Topline Results for Xanamia Phase 2B/3 Alzheimer's Disease Clinical Trial to Mid-Nov This Year
THOMSON REUTERS  ·  10-21 05:55
Actinogen Medical - Narrow Guidance for Topline Results for Xanamia Phase 2B/3 Alzheimer's Disease Clinical Trial to Mid-Nov This Year
Invion - Point8 Capital and Rockford Capital to Cover up to 85% of Invion Clinical Trial Costs
THOMSON REUTERS  ·  10-21 05:52
Invion - Point8 Capital and Rockford Capital to Cover up to 85% of Invion Clinical Trial Costs
Hexima Ltd-Director Appointment/Resignation
THOMSON REUTERS  ·  10-21 05:31
Hexima Ltd-Director Appointment/Resignation
When Will Botanix Pharmaceuticals Limited (ASX:BOT) Breakeven?
Simply Wall St.  ·  10-21 04:02
When Will Botanix Pharmaceuticals Limited (ASX:BOT) Breakeven?
Flight Centre Travel Group And 2 Other Australian Founder Led Stocks To Watch
Simply Wall St.  ·  10-21 00:30
Flight Centre Travel Group And 2 Other Australian Founder Led Stocks To Watch
Catalyst Metals And 2 Australian Growth Stocks To Watch
Simply Wall St.  ·  10-20 21:48
Catalyst Metals And 2 Australian Growth Stocks To Watch
Mesoblast And 2 Australian Insider Backed Growth Stocks To Watch
Simply Wall St.  ·  10-20 17:40
Mesoblast And 2 Australian Insider Backed Growth Stocks To Watch
BHP and National Australia Bank Drag Aussie Shares Lower
Reuters  ·  10-20 14:17
BHP and National Australia Bank Drag Aussie Shares Lower
Starpharma Lifts Stake in Petalion Therapeutics to 66%, Gains Majority Control of Oncology Program
MT Newswires Live  ·  10-20 13:54
Starpharma Lifts Stake in Petalion Therapeutics to 66%, Gains Majority Control of Oncology Program
Starpharma Increases Stake in Petalion to 66% Securing Majority Ownership
Reuters  ·  10-20 09:02
Starpharma Increases Stake in Petalion to 66% Securing Majority Ownership
PolyNovo CFO to Step Down
MT Newswires Live  ·  10-20 09:00
PolyNovo CFO to Step Down
Cynata Therapeutics - Establishes Share Sale Facility for Unmarketable Parcel Holders
THOMSON REUTERS  ·  10-20 07:01
Cynata Therapeutics - Establishes Share Sale Facility for Unmarketable Parcel Holders

Introduction

Company Name.
BK7508
Affiliated Markets:
Listing Date:
--
Main Business:
Issue price:
--